This test analyzes the DMD gene, which is associated with Duchenne and Becker muscular dystrophy.
Test Code | D4045 |
---|---|
Test Summary |
This test analyzes the DMD gene, which is associated with Duchenne and Becker muscular dystrophy. |
Turn Around Time | 3 - 5 weeks |
Acceptable Sample Types | DNA, Isolated , Dried Blood Spots , Saliva , Whole Blood (EDTA) |
Acceptable Billing Types | Institutional Billing , Self (patient) Payment |
NY Approved | Yes |
CPT Codes** | 81161(x1), 81408(x1) |
Self (patient) Price | $935.00 |
---|---|
Institutional Price | $935.00 |
This gene sequencing panel includes both sequencing and deletion/duplication (CNV) analysis for all coding regions of the included genes (unless otherwise noted). All analysis is performed utilizing next-generation sequencing (NGS) technology. All variants are classified according to American College of Genetics and Genomics (ACMG) guidelines.
Duchenne and Becker muscular dystrophies are two related conditions that primary affect skeletal muscles which are used for movement and heart muscle. Duchenne and Becker occur almost exclusively in males. Duchenne and Becker muscular dystrophies have similar signs and symptoms and are caused by different mutations in the same gene. Duchenne and Becker muscular dystrophies together affect 1 in 3500 to 5000 newborn males worldwide and are caused by mutations in the DMD gene. Approximately 60% of pathogenic variants in the DMD gene are deletions of one or more exons, approximately 5% are duplications of one or more exons, and approximately 35% are small pathogenic variants within the exon.
The Agilent Sureselect DMD targeted sequence capture method was used to enrich the entire DMD gene, which includes all exons and introns from this sample's genomic DNA. DNA was analyzed by next-generation sequencing (NGS) on the Illumina MiSeq or NovaSeq™ 6000 with 2x150 paired-end reads. Primary data analysis is performed using Illumina bcl2fastq converter v2.19. Secondary analysis is performed using Illumina DRAGEN Bio-IT Platform v3.10.8. Tertiary analysis for SNVs is performed using SnpEff v5.0 and Revvity Omics' internal ODIN v1.01.66 software. Deletions and duplications within the DMD gene were assessed using BioDiscovery's NxClinical v6.1 software (El Segundo, CA). The interpretation of variants is based on our current understanding of the DMD gene. Interpretations may change over time as more information about this gene becomes available. Variants are evaluated by their frequency in databases such as the Genome Aggregation Database (gnomAD), Human Gene Mutation Database (HGMD), and ClinVar. Variants that have a frequency greater than expected given the prevalence of disease are considered to be benign. Benign and likely benign variants are not reported. Intronic variants beyond +/-3 are not reported unless known or suspected to be pathogenic. Some complex variants may not be detected, including complex rearrangements such as inversions or insertions. In some cases, due to the complexity of the sequence, not all variants in the flanking intronic regions are able to be analyzed. This assay is not designed to detect mosaicism; possible cases of mosaicism may be investigated at the discretion of the laboratory director. Possible diagnostic errors can include sample mix-ups, genetic variants that interfere with analysis, and other sources. A list of all variants identified in this individual is available upon request.
Collection |
Required DNA Quantity by Test Type*:
|
---|---|
Sample Condition |
* Required DNA Quality: High molecular weight DNA (>12kb). A260/A280 reading should be ≥ 1.8. A260/230 a ratio range of 1.8 to 2.2. Contact the laboratory for specific amounts if total ng cannot be met. |
Shipping |
Ship overnight at ambient temperature. |
SPECIAL SAMPLE INSTRUCTIONS |
|
Collection Container(s) |
EDTA (purple top) |
---|---|
Collection |
Infants (< 2-years): 2 to 3 mL; Children (>2-years): 3 to 5 mL; Older children and adults: Minimum 5mL. The blood tube should be inverted several times immediately after blood collection to prevent coagulation. |
Sample Condition |
Store at ambient temperature. Do not refrigerate or freeze. |
Shipping |
Ship overnight at ambient temperature ensuring receipt within 5-days of collection. |
SPECIAL SAMPLE INSTRUCTIONS |
Clotted or hemolyzed samples are not accepted. |
Collection Container(s) |
Oragene™ Saliva Collection Kit or ORAcollect-Dx kit |
---|---|
Collection |
Collect saliva on an Oragene™ Saliva Collection Kit ORAcollect-Dx kit according to the manufacturer's instructions. |
Sample Condition |
Store at ambient temperature. Do not refrigerate or freeze. |
Shipping |
Ship overnight at ambient temperature. |
SPECIAL SAMPLE INSTRUCTIONS |
Please contact Revvity Omics to request the saliva collection kit for patients who cannot provide a blood sample as whole blood is the preferred sample. Testing using Saliva swabs is currently not available for customers in India. Contact the Revvity Omics laboratory for more information. |
Collection Container(s) |
Dried blood spot card |
---|---|
Collection |
Follow kit instructions. Briefly, allow blood to saturate the card until indicated areas are filled and blood has soaked through the card. Air dry the card at ambient temperature for at least 3 hours.
|
Sample Condition |
Follow the instructions provided with the collection set. Store the dried blood at ambient temperature for up to two days. If the specimen cannot be sent as soon as it is dry, the filter paper should be placed in a sealable plastic bag and stored in a refrigerator (≤ 8°C) or preferably in a freezer. |
Shipping |
Follow kit instructions. Double bag and ship overnight at ambient temperature. |
Select the correct test for your patient, and download and fill out the Clinical Genomics test requisition form.
Obtain a sample for testing from the patient using one of the provided Revvity Omics test packs.
Send samples and all required forms back to Revvity for processing using pre-paid shipping label.
We are here to answer your questions.